Global Radiotherapy Market - 2022-2029

Global Radiotherapy Market - 2022-2029

Market Overview

Radiotherapy Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.10% during the forecast period (2022-2029).

Radiotherapy, also known as radiation therapy, is used for cancer patients to cure cancer by destroying cancer cells and reducing the size of tumors. X-rays, gamma rays, and charged particles are commonly used radiations during radiotherapy. Based on the severity of cancer, the radiation beam can be applied externally, internally or systemically. The latest developments in the implementation of Computed tomography-aided intensity-modulated radiotherapy and image-guided techniques are expected to boost the market growth over the forecast period. An increase in demand for cancer treatments is expected to give lucrative opportunities for market growth during the forecast period.

Market Dynamics

The rising prevalence of cancer drives the global radiotherapy market, considerable investments in research and development activities of cancer treatment, technological advancements in radiotherapy devices, rising geriatric population, increasing adoption of radiotherapy devices and procedures, and rise in awareness campaigns regarding the benefits of radiotherapy.

The increasing number of cancer cases propels the global radiotherapy market growth.

Concerning the World Health Organization, cancer is a leading cause of death globally, responsible for over 10 million deaths in 2020. Worldwide, 1 in 6 deaths is because by cancer, and over 70% of deaths from cancer occur in low- and middle-income countries; the most common type of cancer are breast (2.26 million cases in 2020), lung (2.21 million cases in 2020), and colon & rectum cancers (1.93 million cases in 2020). due to increasing life expectancy number of cancer cases diagnosed worldwide each year has risen tremendously, driving the market's growth. Over one-third of cancer deaths are because of 5 leading behavioral and dietary risks: high body mass index, low fruit and vegetable intake, lack of physical activity, tobacco use, and alcohol consumption. For instance, Tobacco use is among the most important risk factors for cancer, with an estimated 8 million people dying annually. It is responsible for approximately 22% of cancer deaths. All these factors are expected to boost the market growth during the forecast period.

The lack of skilled personnel is restraining the global Radiotherapy market growth.

However, the lack of skilled personnel to perform radiotherapy, the presence of alternative treatments, high cost of equipment are likely to hamper the market.

Industry analysis

The global radiotherapy market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing, Etc.

Segment Analysis

External beam radiation therapy is assumed to command the global market throughout the forecast period (2022-2029).

External beam radiation therapy dominated the global radiotherapy market in 2021 and is estimated to dominate throughout the forecast period (2022-2029). Owing to the advancements in external beam radiation therapy such as multileaf collimator, integration of imaging techniques such as positron emission tomography (PET), and computed tomography (CT), the advanced dose calculation algorithms with improved delivery techniques have improved tumor dose dispersal with minimum normal tissue lethality. Moreover, the development of toxicity and particle therapy has enabled easy planning procedures, accurate tumor depiction, and dose estimation, providing effective personalized treatment. For instance, the advantages of 3DCRT, like the improvements of 2D imaging as with the use of CT imaging rather than X-ray imaging, enable more accurate tumor localization by indicating the critical normal organ structures in the imaging, thereby facilitating the estimation of optimal beam placement and shielding to be used. The 3DCRT is often used to treat brain tumors, breast tumors, gastrointestinal cancer, pulmonary carcinoma, gynecologic malignancies, Etc. The 3DCRT and the intensity-modulated radiotherapy (IMRT) have been demonstrated to improve short-term response rates and reduce side effects such as mouth dryness and parotid gland injury, enhancing the quality of life and promoting the prognosis of patients with nasopharyngeal carcinoma.

Geographical Analysis

The North American region holds the largest market share of the global radiotherapy market.

North America dominated the global radiotherapy market in 2021 and is estimated to hold the largest market size over the forecast period (2022-2029) owing to the rising prevalence of cancer, extensive ongoing research and development programs engaged in improving the existing radiation therapy techniques like integration of image-guided and intensity-modulated radiotherapy combined with hormone treatment to reduce remission percentages. The elevating prevalence of cancer is expected to drive the global radiotherapy market over the period forecast. For instance, according to the National Cancer Institute, in 2020, there were 1,806,590 new cancer cases diagnosed in the U.S., with 606,520 deaths; as per the CDC projection, there will be 29.5 million cancer cases by 2040. The rising funding to study radiotherapy services and procedures in the region is expected to drive the market. For instance, on March 01, 2022, Penn Medicine awarded a $12.3M NIH Grant to Study Ultra-Fast, High-Dose FLASH Radiation Therapy for Cancer. The increasing mergers, launches, and acquisitions by the key players related to radiotherapy are expected to boost the market. For instance, on April 5, 2022, Elekta and GE Healthcare collaborated to expand access to precision radiation therapy solutions.

Competitive Landscape

The major players operating in the global radiotherapy market are Varian Medical Systems, Elekta AB, Accuracy Incorporated, IBA (Ion Beam Applications), Nordion, Inc., Isoray Medical, Inc., Research Laboratories AB, Mevion Medical Systems, Inc., and Mitsubishi Electric Corporation, GE Healthcare. The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the radiotherapy market's growth globally. For instance, on September 7, 2022, Accuracy Incorporated partnered with Swiss-based Genolier Innovation Hub to bring medical and technological advances to patients faster. Also, on April 28, 2022, Varian partnered with Icon Group to advance patient-centric solutions.

Accuracy Incorporated

Overview:

Accuracy Incorporated is a leading company that develops, manufactures and sells radiotherapy systems for alternative cancer treatments. Accuracy is committed to innovative designing radiotherapy solutions. Accuracy was founded in 1990 and is headquartered in Sunnyvale, California, the United States, with manufacturing facilities in Madison, Wisconsin, Sunnyvale, California, and Chengdu, China, with regional offices in Hon kong, China, and Tokyo, Japan. Accuracy has around 14 subsidiaries spread across the globe.

Product Portfolio:

The product portfolio of Accuracy Incorporated for radiotherapy has Radixact Treatment Delivery System, TomoTherapy System and CyberKnife S7 stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) system.

The global radiotherapy market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.